Oncolys BioPharma, Inc. (4588) Stock Statistics & Valuation Metrics

Oncolys BioPharma, Inc. has a market cap or net worth of ¥14.91B. The enterprise value is ¥7.81B.

Oncolys BioPharma, Inc. has 24,961,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oncolys BioPharma, Inc.’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -54.63%.

The current PE Ratio of Oncolys BioPharma, Inc. is -6.71. Oncolys BioPharma, Inc.’s PEG ratio is 0.26.

In the last 12 months, Oncolys BioPharma, Inc. had revenue of 31.38M and earned -1.68B in profits. Earnings per share was -77.17.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Oncolys BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Oncolys BioPharma, Inc. upcoming earnings date is Aug 8, 2025, TBA (Confirmed).

Oncolys BioPharma, Inc. as a current ratio of 12.28, with Debt / Equity ratio of 18.23%

In the past 12 months, Oncolys BioPharma, Inc. has paid 3.76M in taxes.

Oncolys BioPharma, Inc. EV to EBITDA ratio is -5.65, with an EV/FCF ratio of -4.68.

Oncolys BioPharma, Inc. has ¥2.41B in cash and marketable securities with ¥324.64M in debt, giving a net cash position of -¥2.09B billion.

Gross margin is 34.67%, with operating margin of -5357.52%, and net profit margin of -5368.27%.

The average price target for Oncolys BioPharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―